产品
编 号：F759301
分子式：C21H19ClN2O5S
分子量：446.9
分子式：C21H19ClN2O5S
分子量：446.9
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 628300-71-0
产品详情
生物活性：
MLN3126 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC50 value of 6.3 nM for calcium influx.
体内研究：
MLN3126 (2.5% w/w; p.o.) decreases colonic level of IFN-γ, largely produced by T cells.MLN3126 (0.05, 0.25 and 1% (w/w); p.o.) has the potential activity for alleviating inflammatory bowel disease (IBD).Animal Model:Activated T cell transferred colitis mouse model
Dosage:0.05, 0.25 and 1% (w/w)(around 4 g/day)
Administration:Oral gavage; 21 days
Result:Blocked CCR9/CCL25 interaction by inhibiting migration of T cells to the colon and resulted in the amelioration of colitis.
体外研究：
MLN3126 inhibits CCL25-induced calcium mobilization with an IC50 value of 6.3 nM in CCR9 expressing cells.MLN3126 inhibits the binding of biotinylated CCL25 to CCR9 with an IC50 of 14.2 nM.
MLN3126 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC50 value of 6.3 nM for calcium influx.
体内研究：
MLN3126 (2.5% w/w; p.o.) decreases colonic level of IFN-γ, largely produced by T cells.MLN3126 (0.05, 0.25 and 1% (w/w); p.o.) has the potential activity for alleviating inflammatory bowel disease (IBD).Animal Model:Activated T cell transferred colitis mouse model
Dosage:0.05, 0.25 and 1% (w/w)(around 4 g/day)
Administration:Oral gavage; 21 days
Result:Blocked CCR9/CCL25 interaction by inhibiting migration of T cells to the colon and resulted in the amelioration of colitis.
体外研究：
MLN3126 inhibits CCL25-induced calcium mobilization with an IC50 value of 6.3 nM in CCR9 expressing cells.MLN3126 inhibits the binding of biotinylated CCL25 to CCR9 with an IC50 of 14.2 nM.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备